Extension maintains listing through March 17, 2026 ROCKAWAY, N.J. , Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National
Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia ROCKAWAY, N.J. , Oct. 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today
ROCKAWAY, N.J. , Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services
Record third quarter 2023 net sales of $4.5 million , an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million Company to host a conference call and webcast today, November 8, 2023 at 4:30 PM EST ROCKAWAY, N.J.
ROCKAWAY, N.J. , Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “ Accessing the Power of Vagus Nerve
ROCKAWAY, N.J. , Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or
electroCore Granted Two New U.S. Patents ROCKAWAY, N.J. , Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark
ROCKAWAY, N.J. , Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress
ROCKAWAY, N.J. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated
ROCKAWAY, N.J. , March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023 , after the close of the market